In brief
- Louisiana (USA) launched a psychedelic-assisted therapy pilot program on August 1.
- The program is funded by a portion of the approximately $600 million the state will receive through 2038 from opioid crisis legal settlements.
- It covers trials involving psilocybin, ibogaine, and MDMA for individuals with opioid use disorder and other treatment-resistant mental health conditions.
The Louisiana Department of Health has launched a pilot program that directs funds from opioid crisis legal settlements to finance clinical trials involving psychedelic substances. The legislation creating the program, Senate Bill 43, went into effect on August 1 after being passed unanimously by both legislative chambers in May.
An unusual funding path
The project, championed by Republican Senator Patrick McMath, became law without the signature of Governor Jeff Landry, who allowed the constitutional deadline to pass without vetoing or signing it. The unique aspect of this case is the source of the money: Louisiana is set to receive approximately $600 million through 2038 from pharmaceutical companies that reached settlements for their role in the opioid epidemic, and a portion of those funds will now be directed toward researching treatments with ibogaine, psilocybin, and MDMA. This marks one of the first instances where a state has explicitly linked opioid crisis restitution funds to psychedelic research.
Who it targets and how it works
The program, managed by the state Department of Health, is designed for individuals with opioid use disorder, co-occurring substance use disorders, or neurological and mental health conditions that have not responded to conventional treatments. The trials must still be processed as investigational new drugs with the FDA and obtain DEA authorization to handle the substances. Furthermore, the law requires specific licensing for therapists facilitating the sessions and mandates the reporting of any incidents. If any of the tested treatments are eventually approved as pharmaceuticals, the law stipulates that at least 2.5% of net sales must revert to state coffers, and it contemplates the possibility of sharing results with a consortium of other states exploring similar pathways for MDMA and other compounds.
What it implies
The program remains in the design phase: having a secured budget does not equate to having active trials, which will depend on the timelines and permits of federal agencies. Even so, the Louisiana case illustrates a shift in tone across several US states, where psychedelic research is beginning to be funded with public money linked to the very crisis the substances seek to address, rather than relying solely on private investment. It is worth reading this with the caution typical of any pilot phase: it defines a framework and a funding source, not clinical results, and its real scope will be known once the first protocols receive federal approval.
Source
- Marijuana Moment. Louisiana Bill To Create Psychedelic Therapy Pilot Program Funded By Opioid Settlement Dollars Takes Effect Without Governor’s Signature. Marijuana Moment, June 26, 2026 (law effective as of August 1, 2026).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
